17 results about "Statin therapy" patented technology

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

Described herein are formulations for the controlled release of statin therapies and methods related thereto.

In various embodiments, the present disclosure provides methods reducing the risk of heart failure in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Described herein are formulations for the controlled release of statin therapies and methods related thereto.

In various embodiments, the present disclosure provides methods of reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising from about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Methods of using visual functions such as dark adaptation, low luminance visual acuity, low luminance deficit, contrast sensitivity and scotopic sensitivity as functional biomarkers for statin therapy in AMD. These biomarkers can be used, for example, to support clinical trials of statin therapy for AMD by identifying participants more likely to respond, by providing an early indication of response, or by serving as an endpoint; or to support treatment of AMD patients with statins by identifying patients more likely to respond, by providing an early indication of responders vs. non-responders, or by confirming a treatment benefit.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

Disclosed are biomarkers that allow statin intolerance to be diagnosed in patients with cardiovascular risk, which is formed by a panel of miRNAs and clinical variables. An in vitro use of let-7c-5p, let-7d-5p, let-7f-5p, miR-376a-3p and / or miR-376c-3p expression levels as biomarkers to diagnose statin intolerance in patients with cardiovascular risk, where overexpression of these biomarkers with respect to the reference values of healthy individuals allows assigning an individual to the group of patients who will suffer adverse effects derived from statin treatment. Also disclosed are a method for detecting statin intolerance, a kit or device, and uses.

The present invention provides methods for treating diseases and disorders associated with elevated lipid and lipoprotein levels. These methods consist of administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient at high cardiovascular risk. In certain formulations, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the example antibody designated mAb316P or alirocumab. The methods of the present invention are useful for treating patients at high cardiovascular risk who have hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled with the maximum tolerated dose of statins.In particular, the methods of the present invention are useful for reducing cardiovascular risk and decreasing atherogenic lipoproteins in patients with high cardiovascular risk during the 12 months following an acute coronary syndrome event, despite treatment with the maximum tolerated dose of statins.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and / or receiving anticoagulant therapy and / or statin therapy.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

In various embodiments, the present invention provides pharmaceutical compositions for use in methods of reducing a risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg / dL to about 500 mg / dL, and administering to the subject a pharmaceutical composition comprising about 4 g of eicosapentaenoic acid ethyl ester per day.